Abstract
Pulmonary arterial hypertension (PAH) in children is associated with various underlying diseases and unknown causes and leads to significant morbidity and mortality. With the discovery of novel drugs and the formulation of evidence-based guidelines, the survival of adult PAH has improved significantly. However, children and adults vary greatly in pathophysiological causes, precipitating factors, clinical manifestations and ultimate outcomes. For achieving a better prognosis in children, offering goal-oriented treatments are essential. This review provides an overview of recent advances of diagnosing and treating PAH in children. Key words: Pulmonary hypertension; Heart disease, congenital; Child
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
